CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma

December 1, 2022 10:47 am Published by

Bexte, T., J. Alzubi, L. M. Reindl, P. Wendel, R. Schubert, E. Salzmann-Manrique, I. von Metzler, T. Cathomen, and E. Ullrich. 2022. CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma. Oncoimmunology 11: 2081415. doi: 10.1080/2162402X.2022.2081415.

Categorised in:

This post was written by Heike Ufheil